CD4 Update

RNS Number : 9982V

Omega Diagnostics Group PLC

20 December 2013

 



Omega Diagnostics Group PLC

("Omega" or the "Company")

CD4 Update

Omega (AIM: ODX), the medical diagnostics company focused on allergy, food intolerance and infectious disease, announces the following update on its CD4 technology transfer project.

As reported last month with the interim results, we selected a preferred manufacturing protocol to proceed to a three-batch validation. The Company is pleased to announce that it has produced a first reference batch which, when tested on patient samples, has produced results which are within the agreed design specification for the accuracy of the test and which demonstrate a significant reduction in the levels of variability previously reported.

This is an important milestone in the technology transfer project and we will proceed to test the protocol with further independent manufacturing runs.

The Board has increased confidence in successfully completing the three-batch validation and, given the proximity to Christmas, we will provide a further update early in the New Year. 

Contacts:

Omega Diagnostics Group PLC	Tel: [phone]
Andrew Shepherd, Chief Executive	www.omegadiagnostics.com
Kieron Harbinson, Group Finance Director
Jag Grewal, Group Sales and Marketing Director
finnCap Ltd	Tel: [phone]
Geoff Nash/Christopher Raggett (Corporate Finance)
Stephen Norcross/Mia Gardner (Corporate Broking)
Walbrook PR Limited	Tel: [phone] or [e-mail]
Paul Cornelius	Mob: [phone]
Lianne Cawthorne	Mob: [phone]

 

END

 

 

MSCTLBTTMBJBBPJ